Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Valeant subpoenaed by US prosecutors over drug pricing

Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N), under fire for price increases of its two heart drugs, said it was subpoenaed by U.S. prosecutors on its pricing, drug distribution and patient assistance programs. Valeant’s U.S.-listed shares were down 9 percent at $156.53 in premarket trading on Thursday. The company, which came under attack from Democratic lawmakers […]

Read More »

FDA declines to expand approval of Pfizer arthritis drug

U.S. health regulators declined to approve Pfizer Inc’s oral rheumatoid arthritis drug Xeljanz to treat moderate to severe cases of the scaly skin condition plaque psoriasis, the drugmaker said on Wednesday. Pfizer said it received a so-called complete response letter from the Food and Drug Administration. Such letters typically outline concerns and conditions that must […]

Read More »

Lilly pill trumps Humira in arthritis study

Eli Lilly and Co’s experimental pill for rheumatoid arthritis proved superior to Abbvie Inc’s leading injectable Humira treatment in a large study, which analysts said could prod them to raise sales forecasts for the medicine. Lilly said on Wednesday it was the first study to show that a once-daily oral treatment was superior to $13 […]

Read More »

Japan’s Astellas looking for more deals to refuel drug pipeline

Japan’s Astellas is seeking more deals to refill its drug pipeline as the pharmaceutical company created through a merger 10 years ago explores opportunities in both established and new therapy areas.   “We’re never satisfied with what we have, so we are looking at strategies to augment the portfolio. Nothing is off the table for […]

Read More »

U.S. prescription opioid misuse and deaths increase

(Reuters Health) – The proportion of people reporting use of prescription opioids for reasons other than medical necessity fell between 2003 and 2013, but use disorders and overdose deaths increased, according to a new study. “The results underscore the importance of addressing the prescription opioid crisis,” said lead author Dr. Beth Han of the Substance Abuse […]

Read More »

Protalix Sells Back ELELYSO Rights to Pfizer for $46 Million

Karmiel, Israel-based Protalix Biotherapeutics, Inc. (PLX) announced today that it was selling its share of a collaboration deal back to Pfizer Inc. (PFE)   Under the original deal, Pfizer took 60 percent and Protalix took 40 percent of revenues and expenses for the development and commercialization of ELELYSO, except in Israel and Brazil. Under the […]

Read More »

Merck cholesterol drug’s odds dim after Lilly failure

The odds that Merck & Co’s high-stakes cholesterol drug will succeed have dropped dramatically after Eli Lilly and Co said its similar medicine failed to reduce heart attacks and strokes, top U.S. heart doctors said. Lilly on Monday said it was halting a 12,000-patient study of its drug, evacetrapib, an oral medication. In earlier studies, […]

Read More »

Collegium Falls in Aftermarket Trading After FDA Delays Ruling on Opioid Painkiller

CANTON, Mass. – Collegium Pharmaceutical, Inc. ’s (COLL) stock is down nearly 10 percent in aftermarket trading after the company announced the U.S. Food and Drug Administration will not complete a review of the company’s extended-release opioid pain medication drug Xtampza.   Michael Heffernan, Collegium’s chairman and chief executive officer, said the company remains confident […]

Read More »

Company Of The Year Gilead: Double The Dose

With not one but two record-shattering product launches that transformed the treatment of hepatitis C, Gilead more than doubled its revenue in a single year, earning its place as Med Ad News’ Company of the Year.

Read More »

Gilead Q&A: Paul Carter, Executive VP Of Commercial Operations

Med Ad News spoke with Paul Carter, Gilead’s executive VP of commercial operations, regarding the success of Sovaldi and Harvoni as well as the company’s vision of the future of biopharmaceuticals.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom